FDA approves dispersible tablet formulation of dolutegravir for HIV in children

This article was originally published here

The approval allows the dispersible tablet formulation of dolutegravir, in combination with other antiretroviral treatments, to be used in treatment-naïve paediatric patients aged more than four weeks and

The post FDA approves dispersible tablet formulation of dolutegravir for HIV in children appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply